Sorafenib: Where do we go from here?
Abby B. Siegel, Sonja K. Olsen, Arthur Magun, Robert S. Brown – 23 June 2010 – The approval of sorafenib as the first effective drug for the treatment of hepatocellular carcinoma (HCC) represents a milestone in the treatment of this disease. A better understanding of HCC pathogenesis has led to the development of several novel targeted treatments. HCC is treated in a uniquely multidisciplinary way requiring surgeons, hepatologists, interventional radiologists, and oncologists.